Ziprasidone-induced tardive dyskinesia [2]

Canadian Journal of Psychiatry

Volumn 50, Issue 9, 2005, Pages 567-568

  Mendhekar, D N ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; PROLACTIN; PYRROLE DERIVATIVE; RISPERIDONE; THYROXINE; TRIFLUOPERAZINE; ZIPRASIDONE;

ADULT; ANAMNESIS; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DYSKINESIA; EMERGENCY CARE; FEMALE; FINGER; GALACTORRHEA; HUMAN; HYPOTHYROIDISM; INDEX FINGER; JAW; LETHARGY; LETTER; PROLACTIN BLOOD LEVEL; PSYCHIATRIC DIAGNOSIS; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCORING SYSTEM; TARDIVE DYSKINESIA; THUMB; WEIGHT GAIN;

EID: 28544439027     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674370505000915     Document Type: Letter

References (4)

1. Gunasekara NS, Spencer CM, Keating GM. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2002;62:1217-51.
2. Carnahan RM, Lund BC, Perry PJ. Ziprasidone, a new atypical antipsychotic drug. Pharmacotherapy 2001;21:717-30.
3. Daniel DG, Zimbroff DL, Potkin SG. Ziprasidone 80mg/day and 160 mg/day in an acute exacerbation of schizophrenia and schizoaffective disorder: a 6-weeks placebo controlled trial. Neuropsychopharmacology 1999;20:491-505.
4. Rosenquest KJ, Waker SS, Ghaemi SN. Tardive dyskinesia and ziprasidone. Am J Psychiatry 2002;159:1436.